

# ChinaAMC Hang Seng Biotech ETF

(Stock Code: 3069 HK/ 9069 HK/ 83069 HK)



Fund Factsheet | As of 31 Oct 2025 New Capital Investment Entrant Scheme (New CIES) Eligible fund

Investment involves risks, including the loss of principal. Past performance is not indicative of future results. Before investing in the ChinaAMC Hang Seng Biotech ETF (the "Fund"), investor should refer to the Fund's prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:

- The Fund aims to provide investment result that, before fees and expenses, closely corresponds to the performance of the Hang Seng Biotech Index (the "Index").
- The Fund is passively managed. Falls in the Index are expected to result in corresponding falls in the value of the Fund.
- The Fund's investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors.
- The Index is a new index. The Fund may be riskier than those tracking more established indices with longer operating history.
- The Fund is subject to concentration risks in biotech companies and in a particular geographical region (i.e. Hong Kong and mainland China). The Fund may be more volatile than a broadly-based fund.
- The Fund is exposed to risks associated with characters of biotech companies, such as pre-revenue, incurrence of net current liabilities, lower liquidity, higher volatility, dependency on intellectual property rights or patents, technological changes, increased regulations and intense competition.
- The Fund is subject to securities lending transactions risks, including the risk that the borrower may fail to return the securities in a timely manner.
- The Fund is subject to tracking error risk.
- If any suspension of the inter-counter transfer of units and/or any limitation on the level of services by brokers and CCASS participants occurs, unitholders will only be able to trade their units in one counter.
- The market price of units traded in each counter may deviate significantly.
- Unitholders will receive distributions in the HKD only. Non HKD based unitholder may have to bear bank or financial institution fees and charges associated with currency conversion.
- The Fund's base currency is HKD but has units traded in USD. Investors may be subject to additional costs or losses associated with foreign currency fluctuations.
- Generally, retail investors can only buy or sell units of the Fund on the SEHK. The trading price of the units on the SEHK is driven by market factors such as the demand and supply of the units. Therefore, the units may trade at a substantial premium or discount to the Fund's NAV.

## Investment Objective

The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Biotech Index.

## Fund Information<sup>1</sup>

|                        |                                                                                                                                                                                                                       |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Investment Manager     | China Asset Management (Hong Kong) Limited                                                                                                                                                                            |
| Trustee                | HSBC Institutional Trust Services (Asia) Limited                                                                                                                                                                      |
| Custodian              | The Hongkong and Shanghai Banking Corporation Limited                                                                                                                                                                 |
| Management Fee         | 0.40% p.a.                                                                                                                                                                                                            |
| Base Currency          | HKD                                                                                                                                                                                                                   |
| Fund Size              | HKD 1,449.26 million                                                                                                                                                                                                  |
| NAV per Unit           | HKD 15.8999                                                                                                                                                                                                           |
| Index                  | Hang Seng Biotech Index (Net Total Return)                                                                                                                                                                            |
| Bloomberg Index Ticker | HSBION Index                                                                                                                                                                                                          |
| Exchange Listing       | The Stock Exchange of Hong Kong Limited - Main Board                                                                                                                                                                  |
| ETF Website            | <a href="https://www.chinaamc.com.hk/product/chinaamc-hang-seng-hong-kong-biotech-index-etf-3069-hk-9069-hk/">https://www.chinaamc.com.hk/product/chinaamc-hang-seng-hong-kong-biotech-index-etf-3069-hk-9069-hk/</a> |

Source: Data as of 31 Oct 2025, Bloomberg, unless specified otherwise.


## Secondary Market Trading Information

|             | Commencement of Dealing | Trading Currency | Trading Board Lot Size | Bloomberg Fund Ticker | ISIN Code    |
|-------------|-------------------------|------------------|------------------------|-----------------------|--------------|
| HKD Counter | 2021-03-18              | HKD              | 100 Units              | 3069 HK Equity        | HK0000711199 |
| USD Counter | 2021-06-30              | USD              | 100 Units              | 9069 HK Equity        | HK0000711199 |
| RMB Counter | 2024-01-19              | RMB              | 100 Units              | 83069 HK Equity       | HK0000711199 |

## Latest Fund Distribution<sup>5</sup>

| Ex-dividend Date | Distribution |
|------------------|--------------|
| 2024-12-18       | HKD 0.0600   |
| 2023-12-18       | HKD 0.0300   |
| 2022-12-19       | HKD 0.0400   |

## Fund Performance<sup>2,4</sup>



## Cumulative Performance (%)<sup>2</sup>

|                                                         | 1 Month | 3 Month | 6 Month | 1 Year | 3 Year | 5 Year |
|---------------------------------------------------------|---------|---------|---------|--------|--------|--------|
| ChinaAMC Hang Seng Biotech ETF <sup>2</sup>             | -10.92  | -4.95   | 40.06   | 75.18  | 60.16  | -      |
| Hang Seng Biotech Index (Net Total Return) <sup>3</sup> | -10.90  | -4.81   | 41.13   | 77.33  | 63.77  | -      |

## Yearly Performance (%)<sup>2</sup>

|                                                         | 2021 <sup>4</sup> | 2022   | 2023   | 2024   | 2025 YTD |
|---------------------------------------------------------|-------------------|--------|--------|--------|----------|
| ChinaAMC Hang Seng Biotech ETF <sup>2</sup>             | -30.99            | -18.31 | -23.59 | -14.68 | 81.55    |
| Hang Seng Biotech Index (Net Total Return) <sup>3</sup> | -31.08            | -17.72 | -23.15 | -14.38 | 83.58    |

1 Please refer to the Fund's prospectus for further details (including fees).

2 Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is calculated on NAV-to-NAV, with dividend reinvested. With effect from 8 November 2021, the investment strategy of the Fund was changed. The performance of the Fund prior to 8 November 2021 was achieved under circumstances that no longer apply. Performance analytics here refer to HKD counter unit. With effect from 5 June 2023, the portfolio of the Fund was rebalanced to reflect the changes to the Index methodology. The performance of the Fund prior to 5 June 2023 was achieved under circumstances that no longer apply.

3 Based on total return, denominated in HKD.

4 Calculated since 17 March 2021, the first official NAV date of the fund.

5 The Manager intends to distribute income to Unitholders at least annually (usually in December), subject to the Manager's discretion, having regard to the Fund's net income after fees and costs. All Units (whether USD, RMB or HKD traded Units) will receive distributions in HKD only. Distributions may be paid out of capital or effectively out of capital as well as income at the Manager's discretion.

Source: China Asset Management (Hong Kong) Limited and Bloomberg unless specified otherwise.

# ChinaAMC Hang Seng Biotech ETF

(Stock Code: 3069 HK/ 9069 HK/ 83069 HK)



Fund Factsheet | As of 31 Oct 2025 New Capital Investment Entrant Scheme (New CIES) Eligible fund

## ▲ Participating Dealers

- ABN AMRO Clearing Hong Kong Limited
- Barclays Bank PLC
- BNP Paribas
- China International Capital Corporation Hong Kong Securities Limited
- China Merchants Securities (HK) Co., Limited
- Citigroup Global Markets Asia Limited
- Credit Suisse Securities (Hong Kong) Limited
- DBS Vickers (Hong Kong) Limited
- Goldman Sachs (Asia) Securities Limited
- Guotai Junan Securities (Hong Kong) Limited
- Haitong International Securities Company Limited
- Huatai Financial Holdings (Hong Kong) Limited
- J.P. Morgan Broking (Hong Kong) Limited
- Korea Investment & Securities Asia Limited
- Merrill Lynch Far East Limited
- Mirae Asset Securities (HK) Limited
- The Hongkong and Shanghai Banking Corporation Limited
- Yue Xiu Securities Company Limited
- Zhongtai International Securities Limited

## ▲ Market Makers

### HKD Counter

- Flow Traders Hong Kong Limited
- Optiver Trading Hong Kong Limited
- Mirae Asset Securities (HK) Limited

### RMB Counter

- Flow Traders Hong Kong Limited


### USD Counter

- Flow Traders Hong Kong Limited
- Optiver Trading Hong Kong Limited

Note: Please refer to the Hong Kong Exchange and Clearing Limited website at [www.hkex.com.hk](http://www.hkex.com.hk) for the latest lists of Market Makers.

## ▲ Portfolio Allocation

### Sector Exposure (%)



## ▲ Top 10 Holdings

| Security Name   | Weight(%) |
|-----------------|-----------|
| WUXI BIOLOGICS  | 11.31%    |
| BEIGENE LT      | 10.23%    |
| INNOVENT BIOLO  | 9.23%     |
| AKESO INC       | 7.24%     |
| SINO BIOPHARMAC | 6.92%     |
| CSPC PHARM GRP  | 5.85%     |
| 3SBIO INC       | 5.61%     |
| WUXI APPTEC CO  | 4.57%     |
| HANSOH PHARMAC  | 4.02%     |
| JD HEALTH INTER | 3.22%     |

Customer Hotline: (852) 3406 8686

Website: [www.chinaamc.com.hk](http://www.chinaamc.com.hk)

Email: [hkfund\\_services@chinaamc.com](mailto:hkfund_services@chinaamc.com)

### Important Note

Investment involves risks. The price of the Fund's units may go up as well as down. Past performance is not indicative of future performance, future return is not guaranteed and a loss of your original capital may occur. This material does not constitute an offer or solicitation of any transaction in any securities or collective investment schemes, nor does it constitute any investment advice. This document is provided for information purposes only and shall not be relied upon for making any investment decision. Certain information or data in this document has been obtained from unaffiliated third parties; we have reasonable belief that such information or data is accurate, complete and up to the date as indicated; China Asset Management (Hong Kong) Limited accepts responsibility for accurately reproducing such data and information but makes no warranty or representation as to the completeness and accuracy of data and information sourced from such unaffiliated third parties. You should read the Fund's offering documents for further details, including risk factors. If necessary, you should seek independent professional advice. This material has been prepared and issued by China Asset Management (Hong Kong) Limited. This material has not been reviewed by the Securities and Futures Commission.

### Index Disclaimer

The Hang Seng Biotech Index is published and compiled by HSIL pursuant to a licence from Hang Seng Data Services Limited ("HSDS"). The mark and name "Hang Seng Biotech Index" is proprietary to HSDS. HSIL and HSDS have agreed to the use of, and reference to, the Hang Seng Biotech Index by the Manager and the Trustee and their respective duly appointed agents in connection with ChinaAMC Hang Seng Biotech ETF, but neither HSIL nor HSDS warrants or represents or guarantees to any broker or holder of the ChinaAMC Hang Seng Biotech ETF or any other person (i) The accuracy or completeness of the Hang Seng Biotech Index and its computation or any information related thereto; or (ii) The fitness or suitability for any purpose of the Hang Seng Biotech Index or any component or data comprised in it; or (iii) The results which may be obtained by any person from the use of the Hang Seng Biotech Index or any component or data comprised in it for any purpose, and no warranty or representation or guarantee of any kind whatsoever relating to the Hang Seng Biotech Index is given or may be implied. The process and basis of computation and compilation of the Hang Seng Biotech Index and any of the related formula or formulae, constituent stocks and factors may at any time be changed or altered by HSIL without notice. To the extent permitted by applicable law, no responsibility or liability is accepted by HSIL or HSDS (i) In respect of the use of and/or reference to the Hang Seng Biotech Index by the manager in connection with ChinaAMC Hang Seng Biotech ETF; or (ii) For any inaccuracies, omissions, mistakes or errors of HSIL in the computation of the Hang Seng Biotech Index; or (iii) for any inaccuracies, omissions, mistakes, errors or incompleteness of any information used in connection with the computation of the Hang Seng Biotech Index which is supplied by any other person; or (iv) For any economic or other loss which may be directly or indirectly sustained by any broker or holder of the ChinaAMC Hang Seng Biotech ETF or any other person dealing with ChinaAMC Hang Seng Biotech ETF as a result of any of the aforesaid, and no claims, actions or legal proceedings may be brought against HSIL and/or HSDS in connection with ChinaAMC Hang Seng Biotech ETF in any manner whatsoever by any broker, holder or any other person dealing with ChinaAMC Hang Seng Biotech ETF. Any broker, holder or other person dealing with ChinaAMC Hang Seng Biotech ETF does so therefore in full knowledge of this disclaimer and can place no reliance whatsoever on HSIL and HSDS. For the avoidance of doubt, this disclaimer does not create any contractual or quasi-contractual relationship between any broker, holder or other person and HSIL and/or HSDS and must not be construed to have created such relationship.